These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 38659046)
1. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. Xu J; Wang BY; Yu SH; Chen SJ; Yang SS; Liu R; Chen LJ; Hou J; Chen Z; Zhao WH; He AL; Mi JQ; Chen SJ J Hematol Oncol; 2024 Apr; 17(1):23. PubMed ID: 38659046 [TBL] [Abstract][Full Text] [Related]
2. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Park JH; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff P; Jeyakumar D; Feng C; Dong J; Shen T; Milletti F; Rossi JM; Vezan R; Masouleh BK; Houot R Lancet; 2021 Aug; 398(10299):491-502. PubMed ID: 34097852 [TBL] [Abstract][Full Text] [Related]
3. BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma. Wang T; Yang Y; Ma L; Feng R; Li J; Zhang C; Bai J; Ding Y; Liu G; Wu F; Lu X; Feng S; Li Z; He T; Li J; Liu H J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39313307 [TBL] [Abstract][Full Text] [Related]
4. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone. Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924 [TBL] [Abstract][Full Text] [Related]
5. BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma. Yan Y; Tu Y; Cheng Q; Zhang J; Wang E; Deng Z; Yu Y; Wang L; Liu R; Chu L; Kang L; Liu J; Li X J Transl Med; 2024 Nov; 22(1):1087. PubMed ID: 39614361 [TBL] [Abstract][Full Text] [Related]
6. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences. Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159 [TBL] [Abstract][Full Text] [Related]
7. [Clinical analysis of the correlation between the expression of soluble B cell maturation antigen and the efficacy of chimeric antigen receptor T cell targeting B cell maturation antigen in patients with multiple myeloma]. Gao SQ; Mu J; Li X; Wang J; Cui R; Li JY; Sui T; Deng Q Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):378-382. PubMed ID: 38951066 [No Abstract] [Full Text] [Related]
8. Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma. Guo J; Wu Q; Li H; Liang C; Dai J; Zhang S; Dai C; Zhang J; Wen Y; Yang W Front Immunol; 2024; 15():1435934. PubMed ID: 39606226 [TBL] [Abstract][Full Text] [Related]
10. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant. Langer P; John L; Monsef I; Scheid C; Piechotta V; Skoetz N Cochrane Database Syst Rev; 2024 May; 5(5):CD013595. PubMed ID: 38695605 [TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial. Chen N; Pu C; Zhao L; Li W; Wang C; Zhu R; Liang T; Niu C; Huang X; Tang H; Wang Y; Yang H; Jia B; Jiang X; Han G; Wang W; Chen D; Wang Y; Rowinsky EK; Kennedy E; Lu VX; Cui G; Wu Z; Xiao L; Cui J JAMA Oncol; 2024 Nov; 10(11):1532-1536. PubMed ID: 39298141 [TBL] [Abstract][Full Text] [Related]
12. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. Iyer SP; Sica RA; Ho PJ; Prica A; Zain J; Foss FM; Hu B; Beitinjaneh A; Weng WK; Kim YH; Khodadoust MS; Huen AO; Williams LM; Ma A; Huang E; Ganpule A; Nagar SD; Sripakdeevong P; Cullingford EL; Karnik S; Dequeant ML; Patel JN; He XS; Li Z; He QA; Mendonez JH; Keegan A; Horwitz SM Lancet Oncol; 2024 Nov; ():. PubMed ID: 39617017 [TBL] [Abstract][Full Text] [Related]
13. Collagenase injection versus limited fasciectomy surgery to treat Dupuytren's contracture in adult patients in the UK: DISC, a non-inferiority RCT and economic evaluation. Dias J; Tharmanathan P; Arundel C; Welch C; Wu Q; Leighton P; Armaou M; Corbacho B; Johnson N; James S; Cooke J; Bainbridge C; Craigen M; Warwick D; Brady S; Flett L; Jones J; Knowlson C; Watson M; Keding A; Hewitt C; Torgerson D Health Technol Assess; 2024 Dec; 28(78):1-262. PubMed ID: 39644138 [TBL] [Abstract][Full Text] [Related]
14. What Are the Functional, Radiographic, and Survivorship Outcomes of a Modified Cup-cage Technique for Pelvic Discontinuity? Mu W; Xu B; Wahafu T; Wang F; Guo W; Zou C; Cao L Clin Orthop Relat Res; 2024 Dec; 482(12):2149-2160. PubMed ID: 38991223 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies. Touzeau C; Krishnan AY; Moreau P; Perrot A; Usmani SZ; Manier S; Cavo M; Martinez Chamorro C; Nooka AK; Martin TG; Karlin L; Leleu X; Bahlis NJ; Besemer B; Pei L; Stein S; Wang Lin SX; Trancucci D; Verona RI; Girgis S; Miao X; Uhlar CM; Chastain K; Garfall AL Blood; 2024 Dec; 144(23):2375-2388. PubMed ID: 39172760 [TBL] [Abstract][Full Text] [Related]
16. A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant. LeBlanc R; Thiant S; Terra R; Ahmad I; Claveau JS; Bambace N; Bernard L; Cohen S; Delisle JS; Lachance S; Kiss T; Roy DC; Sauvageau G; Roy J Curr Oncol; 2024 Nov; 31(11):7258-7274. PubMed ID: 39590165 [TBL] [Abstract][Full Text] [Related]
17. [Construction of CD138-targeted chimeric antigen receptor- modified T cells and their effect in multiple myeloma therapy]. Guo CC; Lu Y; Tang KJ; Xing HY; Tian Z; Rao Q; Wang M; Xiong DS; Wang JX Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):436-444. PubMed ID: 38964917 [No Abstract] [Full Text] [Related]
18. Tamoxifen for adults with hepatocellular carcinoma. Naing C; Ni H; Aung HH Cochrane Database Syst Rev; 2024 Aug; 8(8):CD014869. PubMed ID: 39132750 [TBL] [Abstract][Full Text] [Related]
19. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis. Yang Y; Chen W; Dong L; Duan L; Gao P Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495 [TBL] [Abstract][Full Text] [Related]
20. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial. Kim P; Sanchez AM; Penke TJR; Tuson HH; Kime JC; McKee RW; Slone WL; Conley NR; McMillan LJ; Prybol CJ; Garofolo PM Lancet Infect Dis; 2024 Dec; 24(12):1319-1332. PubMed ID: 39134085 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]